Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:G01N33/48

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/182807PROCESS FOR THE PREPARATION OF LIPIDATED PROTEINACEOUS STRUCTURES
WO 17.09.2020
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Appl.No PCT/EP2020/056339 Applicant MERCK PATENT GMBH Inventor WOELL, Steffen
The present invention relates to a process for the preparation of a conjugate, comprising a biological molecule, an enzymatic tag, a hydrophilic spacer, a linker and a lipophilic moiety using enzymatic coupling. A component comprising an enzymatic tag (e.g. a pentaglycine moiety), a hydrophilic spacer, a linker and a lipophilic moiety (e.g. lipid) is coupled enzymatically via to the biological molecule in an aqueous medium and subsequently purified. A C- terminal motif (LPXTG) for enzymatic conjugation by transpeptidases, e.g. sortase A is preferably present. Intended for linking biomolecules to e.g. liposomes, exosomes or for surface modification. Example of the component to be linked: DMA-PEG-G5.
2.WO/2020/184377METHOD FOR FABRICATING ANALYSIS SUBSTRATE, ANALYSIS SUBSTRATE, AND ANALYSIS UNIT
WO 17.09.2020
Int.Class G01N 37/00
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
37Details not covered by any other group of this subclass
Appl.No PCT/JP2020/009410 Applicant JVCKENWOOD CORPORATION Inventor TSUJITA Koji
A method for fabricating an analysis substrate comprises immobilizing, on an analysis substrate (10), antibodies (41) for reacting specifically with a specific antigen (52) possessed by a substance (50) to be detected. The analysis substrate (10) is immersion-treated with a predetermined treatment liquid, and antibody aggregates (42) in which the antibodies (41) are aggregated are formed in boundary regions between recesses and projections on the analysis substrate (10). The antigen (52) and the antibodies (41) are reacted, and the substance (50) to be detected is captured on the analysis substrate (10) by the antibody aggregates (42).
3.WO/2020/184877GAS CIRCULATION APPARATUS FOR INHALATION TEST
WO 17.09.2020
Int.Class A61D 7/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
DVETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
7Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
04Devices for anaesthetising animals by gases or vapours; Inhaling devices
Appl.No PCT/KR2020/002930 Applicant KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION Inventor KIM, Jae Young
A gas circulation apparatus for an inhalation test according to an embodiment comprises: a chamber for accommodating a test subject; an introducing part for introducing a sample into the chamber; a circulation part for promoting the circulation of a gas inside the chamber; and a circulation pipe connected to the chamber and the circulation part so as to communicate with the chamber and the circulation part, wherein the chamber can rotate to induce a change in the environment inside the chamber and induce natural inhalation in a test animal.
4.WO/2020/186007METHODS FOR CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS
WO 17.09.2020
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
Appl.No PCT/US2020/022294 Applicant CRESCENDO BIOSCIENCE, INC. Inventor CURTIS, Jeffrey R.
This invention includes methods for assessing and treating risk of cardiovascular disease (CVD) in a subject with an inflammatory disease, for example rheumatoid arthritis (RA). Provided are methods for assessing risk, for recommending therapy, for prognosis and monitoring, and for treatment, which are advantageously accurate for CVD in RA. The methods include measuring quantitative data for biomarkers, calculating a CVD risk score for a subject using training data, and validating the CVD risk score with a set of validation clinical data.
5.WO/2020/186057BIOMARKERS FOR JOINT AILMENTS AND USES THEREOF
WO 17.09.2020
Int.Class A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
Appl.No PCT/US2020/022389 Applicant NOVUS INTERNATIONAL INC. Inventor CHEN, Juxing
The present invention relates to biomarkers that are associated with joint disorders, and methods of using the biomarkers diagnose joint ailments, monitor the progression of joint ailments, determine when treatments is indicated, and monitor the efficiency of treatment. Also provided are methods for treating joint ailments, which comprise administering chelated trace minerals to animals diagnosed with or predisposed to having joint ailments.
6.WO/2020/181846CYSTEINE-CONTAINING ANTIBODY, DRUG CONJUGATE AND USE THEREOF
WO 17.09.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2019/123219 Applicant XDCEXPLORER (SHANGHAI) CO., LTD. Inventor XIE, Zhenhui
Provided are a cysteine-containing antibody, a drug conjugate and a use thereof. The heavy chain constant region of the antibody is a humanized γ1 chain, and the light chain constant region thereof is a humanized κ chain, wherein amino acid residues at an A site of the heavy chain constant region and/or at a B site of the light chain constant region are replaced with cysteine, so as to provide an active site for site-directed coupling with drugs.
7.WO/2020/183916BLOOD-SUGAR LEVEL CALCULATION PROGRAM, BLOOD-SUGAR LEVEL CALCULATION METHOD, AND BLOOD-SUGAR LEVEL MEASUREMENT DEVICE
WO 17.09.2020
Int.Class G01N 33/66
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
66involving blood sugars, e.g. galactose
Appl.No PCT/JP2020/001985 Applicant TERUMO KABUSHIKI KAISHA Inventor SATO Hiroya
in order to calculate the blood-sugar level of a specimen containing plasma and blood cells on the basis of a measurement result of a coloring amount of a coloring pigment on a blood-sugar level measurement chip having a reagent which reacts with glucose contained in the specimen and causes the coloring pigment to develop a color, this blood-sugar level calculation program causes a processor to execute a first step for calculating a relational expression between the measurement result and the blood-sugar level of the specimen on the basis of a prescribed model. The specimen has prescribed parameters including at least the blood-sugar level. The prescribed model is represented as a diffusion reaction model of a one-dimensional coordinate system. The diffusion reaction model is represented by a viscosity change of the reagent over time, a concentration change of the glucose contained in the plasma over time, a concentration change of the reagent over time, and a coloring amount change of the reagent over time.
8.WO/2020/184676METHOD FOR HIGH-THROUGHPUT EVALUATION OF NMDA RECEPTOR INHIBITION ACTIVITY
WO 17.09.2020
Int.Class C12Q 1/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
02involving viable microorganisms
Appl.No PCT/JP2020/010909 Applicant NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY Inventor SHIRAO, Tomoaki
The present invention addresses the problem of establishing a method for the direct, rapid and simple high-throughput evaluation of an NMDA receptor inhibition activity. An NMDA receptor inhibition activity can be evaluated with high throughput by a method comprising the following steps in this order: (A) bringing a substance of interest into contact with cultured neurons; (B) bringing the cultured neurons into contact with a glutamate solution; (C) immobilizing the cultured neurons; (D) visualizing drebrin clusters of dendritic spines of the cultured neurons; and (E) measuring the line density along the dendrites of the drebrin clusters, and determining that the substance of interest has an NMDA receptor inhibition activity when the line density is higher than the line density of the cultured neurons that are not contacted with the substance of interest.
9.WO/2020/184806INTEGRIN ΑVΒ3 TARGETING PROBE FOR DIAGNOSING RETINAL AND CHOROIDAL NEOVASCULAR DISEASES, AND PREPARATION METHOD THEREFOR
WO 17.09.2020
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Appl.No PCT/KR2019/015132 Applicant SEOUL NATIONAL UNIVERSITY HOSPITAL Inventor LEE, Byung Chul
Provided are: an integrin targeting probe, which can be effectively used for the diagnosis or treatment of retinal and choroidal neovascularization or age-related macular degeneration by predicting the occurrence and recurrence of retinal and choroidal neovascularization before structural changes of retinal and choroidal neovascularization occur; and a preparation method therefor. The integrin targeting probe is an integrin αvβ3 targeting probe for diagnosing retinochoroidal neovascular diseases and can comprise a fluorescence-labeled cyclic RGD peptide, which is completed by conjugating an NH2-cyclic RGD peptide precursor to a fluorescent material.
10.WO/2020/185646METHOD AND SYSTEM FOR VISUALIZATION OF ENDOTOXINS IN A FLUID SAMPLE
WO 17.09.2020
Int.Class G01N 33/579
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
579involving limulus lysate
Appl.No PCT/US2020/021642 Applicant BL TECHNOLOGIES, INC. Inventor LEDRU, Sukmi
Exemplified methods and systems facilitate presentation of data derived from measurements of endotoxins in fluid samples. In particular, the exemplified methods and systems facilitate presentation of such measurements in a graphical user interface and/or in a report for endotoxin concentrations in a fluid sample. The presentation facilitates a unified and intuitive graphic visualization that are presented within a single interactive interface and/or report.